Welcome to our dedicated page for Harrow news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow stock.
Harrow, Inc. commercializes ophthalmic disease management products in North America, with a portfolio used in dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions and retina diseases. Its recurring news includes financial results and stockholder letters, commercial product updates for therapies such as VEVYE, ILEVRO, IOPIDINE and TRIESENCE, and distribution arrangements supporting U.S. product availability.
Company updates also cover reimbursement and regulatory developments, scientific presentations in ophthalmology, clinical development for label expansion, product launches and capital actions such as senior unsecured notes. Harrow reports through branded ophthalmic pharmaceuticals and ImprimisRx, reflecting both commercial products and specialty ophthalmic medication operations.
Harrow (Nasdaq: HROW) announced that management will participate in three investor conferences in New York in September 2026: the Cantor Global Healthcare Conference on September 9 at 1:35 p.m. ET, Lake Street Capital Markets Best Ideas Growth Conference on September 10, and H.C. Wainwright Global Investment Conference on September 15 at 11:00 a.m. ET. Fireside chats at Cantor and H.C. Wainwright will be webcast live and archived for about 90 days on Harrow’s website Events page.
Harrow (Nasdaq: HROW) reported new data from a prospective, randomized, contralateral-eye study of IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% in 50 adults (100 eyes) receiving same-day bilateral intravitreal injections.
Each patient received IHEEZO in one eye and preservative-containing proparacaine 0.5% in the fellow eye, after 2% lidocaine-soaked pledgets in both eyes. According to Harrow, patients reported approximately 58% less overall discomfort in the IHEEZO-treated eye, with statistically significant differences at all four post-injection assessments (all p≤0.048) on a 0–10 numeric rating scale.
The largest absolute differences occurred when discomfort is typically highest, immediately after injection: scores of 1.44 vs 3.06 at two minutes and 1.26 vs 2.82 at one hour, favoring IHEEZO. Lower discomfort scores with IHEEZO persisted through the 24-hour assessment. IHEEZO is indicated for ocular surface anesthesia; the most common adverse reaction is mydriasis (approximately 25%), and it is contraindicated in patients with hypersensitivity to any component.
Harrow (Nasdaq: HROW) reported second quarter 2026 revenue of $70.7 million, up 60% sequentially and 11% year over year, with gross margin of 71%. Net loss was $17.3 million versus net income of $5.0 million a year ago, and Adjusted EBITDA was $(1.2) million versus $17.0 million. Cash and cash equivalents were $83.9 million at June 30, 2026.
VEVYE generated $29.4 million in quarterly revenue, up about 40% sequentially and 58% year over year, with branded TRx market share rising to 14.6%. IHEEZO revenue was $15.6 million with record unit demand, and TRIESENCE unit demand rose 162% year over year. Harrow announced the planned acquisition of TYRVAYA, launched BYOOVIZ in July 2026, and reiterated full-year 2026 guidance of $350–$365 million in revenue and $80–$100 million in Adjusted EBITDA.
Harrow (Nasdaq: HROW) agreed to acquire global rights to TYRVAYA (varenicline solution) nasal spray 0.03 mg for dry eye disease from Viatris. TYRVAYA is approved in the U.S., China, and Taiwan, with additional marketing applications pending, and complements Harrow’s flagship VEVYE eye-drop franchise through a different mechanism of action.
According to Harrow, the deal includes $30 million cash at closing plus up to $70 million in sales-based milestone payments, funded initially from cash on hand. Closing is expected in the second half of 2026, subject to customary conditions, and management expects the transaction to be financially accretive shortly after closing.
Harrow (Nasdaq: HROW) will report second quarter 2026 financial results for the period ended June 30, 2026, after the market close on Monday, August 10, 2026. The company will post its Letter to Stockholders and host a conference call and webcast at 8:00 a.m. ET on Tuesday, August 11, 2026, with replay available on its investor website for one year.
Harrow (Nasdaq: HROW) and Samsung Bioepis reported interim results from a large, real-world Phase 4 post-marketing surveillance study of SB11 (BYOOVIZ / AMELIVU), a biosimilar to Lucentis, conducted in the Republic of Korea and presented at ASRS 2026.
The open-label, prospective, multicenter study (May 2022–May 2026) followed patients for up to 24 weeks after first dose. Interim data covered 298 patients (182 treatment‑naïve, 116 switched from other anti‑VEGF therapies). Mean best‑corrected visual acuity (BCVA) improved by -0.10 (SD 0.29) in treatment‑naïve and -0.03 (SD 0.24) in switched patients (P=0.0239). Mean central subfield thickness (CST) changed by -95 (SD 125) µm and -53 (SD 108) µm, respectively (P=0.0168). Disease duration was significantly associated with BCVA (P=0.0003) and CST (P=0.001) outcomes, and no new safety concerns were identified, which Samsung Bioepis and Harrow said supports confidence in SB11’s real‑world use.
Harrow (Nasdaq: HROW) reported three study presentations on IHEEZO and BYOOVIZ at the ASRS 2026 Annual Meeting, adding to clinical and real‑world evidence for its retina portfolio. According to Harrow, an interim, investigator‑initiated randomized study in 150 intravitreal injection patients comparing IHEEZO with subconjunctival lidocaine showed early trends toward less post‑procedure pain, improved post‑injection experience, and fewer ocular symptoms over 24 hours in the IHEEZO group.
Harrow continues enrolling QUELL, a prospective, randomized, multicenter IHEEZO trial in about 236 subjects under an active IND, with topline data expected in Q4 2026. A separate retrospective real‑world analysis of nearly 20,000 injections found no evidence that IHEEZO’s low‑viscosity gel formulation increased endophthalmitis risk versus a legacy tetracaine/povidone‑iodine regimen. Samsung Bioepis also presented interim findings from a large post‑marketing BYOOVIZ surveillance study, with full results being announced jointly with Harrow.
Harrow (Nasdaq:HROW) announced the U.S. commercial launch of BYOOVIZ (ranibizumab-nuna), an FDA-approved, interchangeable biosimilar referencing LUCENTIS for Wet AMD, RVO-related macular edema, and mCNV.
Harrow holds exclusive U.S. commercialization rights to BYOOVIZ and OPUVIZ, expanding its retina portfolio alongside IHEEZO and TRIESENCE in a roughly $9 billion U.S. anti-VEGF market.
Harrow (Nasdaq:HROW) and Samsung Bioepis announced the US relaunch of BYOOVIZ (ranibizumab-nuna), an interchangeable biosimilar to Lucentis, under a commercialization partnership. Samsung Bioepis handles development, regulatory registration, and manufacturing, while Harrow leads US commercialization of both BYOOVIZ and OPUVIZ (aflibercept-yszy).
BYOOVIZ is FDA-approved and interchangeable for treating wet AMD, macular edema following RVO, and mCNV. OPUVIZ, interchangeable to Eylea, is indicated for wet AMD, RVO-related macular edema, DME, and DR.
Harrow (Nasdaq:HROW) announced the re-launch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, indicated for all forms of vernal keratoconjunctivitis (VKC) in children and adults.
The topical calcineurin inhibitor targets underlying VKC inflammation, showed statistically significant trial results, and is backed by physician education, access, and affordability programs to improve long-term pediatric eyecare.